[Featured Stock] Genenbio Rises on News of 27 Billion KRW Paid-in Capital Increase
[Asia Economy Reporter Jang Hyowon] ZenenBio is showing strong performance following the news of its decision to conduct a paid-in capital increase worth 27 billion KRW.
As of 9:53 AM on the 21st, ZenenBio is trading at 2,790 KRW, up 14.81% compared to the previous day.
On this day, ZenenBio announced that it decided to conduct a third-party allotment paid-in capital increase worth 15 billion KRW targeting its largest shareholder, Genexine, and Devro DNC. Additionally, it decided on a third-party allotment paid-in capital increase worth approximately 12 billion KRW targeting JS Value Partners and RSH Group.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The funds raised through the paid-in capital increase will be used for the remaining payment for the waste treatment facility land in Gyeongsan Knowledge Industry District, construction costs for the Pyeongtaek ZenenCore Center, and operating expenses.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
